BioCentury
ARTICLE | Company News

Hana to in-license cancer compounds

March 18, 2006 2:37 AM UTC

HBX signed a letter of intent to in-license from Inex (TSX:IEX) exclusive, worldwide rights to three cancer compounds formulated with next-generation liposomal delivery technology, including Marqibo sphingosomal vincristine. IEX will receive US$11.5 million up front in cash and stock and is eligible for milestones of up to US$30.5 million in stock, plus royalties.

Hana will seek an SPA for Phase III trials of Marqibo in non-Hodgkin's lymphoma (NHL) and acute lymphocytic leukemia (ALL), which the company hopes to begin this year. Last year, IEX received a not approvable letter for Marqibo to treat relapsed, aggressive NHL. The company was seeking accelerated approval based on results from a single-arm Phase IIb trial. ...